3-indolepropionic acid (IPA) production

Certain gut bacteria make 3-indolepropionic acid (IPA) from tryptophan. Tryptophan is a building block of dietary protein. Higher IPA concentrations in blood have been associated with a lower risk of developing type 2 diabetes, which has drawn attention to the bacteria that produce it.

This stool test uses bacterial DNA to estimate your gut community’s potential to produce IPA. It’s an exploratory measurement. Its value for predicting your personal disease risk or guiding treatment hasn’t been established, and there’s no validated health target for the result.

Where This Compound Comes From

Bacteria in the colon can convert tryptophan into IPA through a series of chemical reactions. Clostridium sporogenes is one of the best-studied producers, and some other Clostridium and Peptostreptococcus species can make it too. Production depends on the particular species and strain, so a broad bacterial group count doesn’t establish how much IPA your gut can produce.

Experiments in bacterial cultures and mice have identified genes needed for this process. Disabling one of those genes stopped IPA production in the studied bacteria. Human antibiotic experiments also support a predominantly microbial source for circulating IPA.

Production Potential, Stool Concentration, and Blood Levels

These are three different measurements. This result estimates production potential from microbial DNA. A chemical measurement of IPA in stool measures the amount remaining in the sample. A blood measurement reflects IPA that has been produced, absorbed, distributed, and cleared.

Having the relevant bacterial genes doesn’t establish that they’re active or that enough starting material is available. The same production estimate can therefore accompany different stool or blood concentrations. Most disease studies measured IPA in blood, and their findings cannot be translated into a risk percentage for your stool result.

Type 2 Diabetes and Insulin Resistance

The strongest human evidence concerns circulating IPA and diabetes. A meta-analysis of eight prospective studies found about 18% lower risk of developing type 2 diabetes for each standard deviation higher blood IPA. A standard deviation describes how widely values vary within a study. The size of the association differed across studies.

An analysis of 13,032 US adults also linked higher circulating IPA with lower subsequent diabetes risk. A separate part of that research examined diet and stool bacteria in 287 men. Fiber intake and particular bacterial species were associated with circulating IPA, although many of those species were not established IPA producers.

In Finnish adults at increased risk of diabetes, higher serum IPA was associated with greater fiber intake and lower levels of an inflammation marker. These findings support studying IPA as part of the relationship between diet, gut bacteria, and metabolism. They don’t establish that low stool production potential causes insulin resistance or that raising this result prevents diabetes.

Heart and Blood Vessels

Several studies have linked circulating IPA with cardiovascular outcomes. Two also examined stool bacteria, but their research scores were built from bacterial groups associated with blood IPA. Those scores are different from this production-potential measurement.

The Chinese study measured arterial stiffness only at follow-up, so it couldn’t establish whether arteries stiffened more slowly. The large US cohort analysis found no association between circulating IPA and coronary heart disease. The cardiovascular evidence remains observational and varies by population and outcome.

Liver Fat, the Gut Lining, and Severe Illness

Some liver studies measured IPA itself in stool, which is closer to the gut but still different from this DNA-based production estimate. Stool IPA was lower in a small study of people with metabolic dysfunction-associated fatty liver disease. In another study of 247 people, including healthy controls, stool IPA was lower in alcohol-related hepatitis and cirrhosis. These comparisons were cross-sectional, so they couldn’t establish which change came first.

Animal and cell experiments suggest that IPA can influence signals that help maintain the intestinal lining and limit inflammation. These mechanisms offer a possible explanation for some human associations. They don’t establish that this stool result measures the strength or permeability of your gut lining.

In a study of 41 people with sepsis, measured stool IPA was lower than in controls and was associated with organ failure severity and survival over the following 28 days. The study was small and involved people who were already severely ill. It doesn’t validate stool production potential as a screening test for infection or future mortality.

Brain and Cognition

Human studies have reported lower circulating IPA in groups with mild cognitive impairment or Alzheimer’s disease. In a separate study of 103 surgical patients, lower plasma IPA before surgery was associated with a higher chance of postoperative delirium. Delirium is a sudden disturbance in attention and awareness.

Possible protective effects on brain cells have been studied in mice and cell cultures. The human associations don’t establish whether lower IPA contributes to disease or follows changes in diet, medication, and gut function. This stool production estimate hasn’t been validated for predicting cognitive decline or postoperative confusion.

When Results Can Be Misleading

• Potential versus activity: bacterial DNA indicates possible functions. It doesn’t directly measure whether those functions are active or how much IPA is being made.
• Recent antibiotics: treatment can change the gut community. A result during recovery may differ from your usual pattern, without establishing lasting damage.
• Diet and bowel transit: recent eating patterns and how quickly material moves through your bowel can affect the sampled community. A change during diarrhea may be difficult to compare with your usual stool pattern.
• Species and strain differences: bacteria within the same broad group can have different genes. The presence of Clostridium or Bifidobacterium alone doesn’t prove IPA production.
• Collection and analysis: preservation, DNA extraction, sequencing, and the reference databases used to interpret microbial genes can affect the estimate. Results from different laboratories or methods are not directly interchangeable.

Understanding a Trend

Repeated measurements may show changes in the sampled gut community, but there’s no established size of change that represents a meaningful improvement in health. A higher production estimate also doesn’t guarantee a higher blood IPA concentration. Trends remain exploratory until studies connect changes in this specific measurement with outcomes that matter to you.